title: Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody.
abstract: OBJECTIVE
  We describe a new rabbit monoclonal antibody, raised against a fixation-resistant epitope of the transcription regulator LIM domain only 2 (LMO2).
  
  
  RESULTS
  Lymphoma cell lines and a large series of normal and neoplastic samples were investigated by Western blot and immunohistochemistry. The antibody detected nuclear positivity for the protein, with the exception of a proportion of classical Hodgkin lymphomas (HLs), peripheral T cell lymphomas (PTCLs) and solid tumours that showed granular cytoplasmic staining. In normal lympho-haematopoietic tissues, LMO2 was expressed at different intensities by CD34(+) blasts, haematopoietic precursors, germinal centre (GC), mantle and splenic marginal zone B cells. While reactive with only scattered elements in the thymus and nine of 237 PTCLs, the antibody stained 31 of 39 T-acute lymphoblastic lymphoma/leukaemias (T-ALLs) and the T-ALL-derived human leukaemic cell line, CCRF-CEM. LMO2 was found in 88% of B-acute lymphoblastic lymphoma/leukaemias (B-ALLs), 5% chronic lymphocytic leukaemias (CLLs) and 14%, 57% and 41% of mantle, follicular and Burkitt lymphomas, respectively. In the setting of diffuse large B cell lymphomas (DLBCLs), LMO2-positivity was related strongly to a GC phenotype. LMO2 was found in 83% primary mediastinal large B cell lymphomas (PMBLs) and 100% nodular lymphocyte predominant Hodgkin lymphomas (NLPHLs), whereas only 10% of classical HLs were stained. Acute and chronic myeloid leukaemias were usually positive.
  
  
  CONCLUSIONS
  The new anti-LMO2 antibody can be applied confidently to routine sections, contributing to the differential diagnosis of several lymphoma subtypes, subtyping of DLBCLs and potential development of innovative therapies.
authors.affiliation: Section of Haematopathology, Department of Haematology and Oncological Sciences Seràgnoli, S Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. t.marafioti@ucl.ac.uk
authors.forename: Claudio
authors.initials: C
authors.lastname: Agostinelli
authors.forename: Jennifer C
authors.initials: JC
authors.lastname: Paterson
authors.forename: Rajeev
authors.initials: R
authors.lastname: Gupta
authors.forename: Simona
authors.initials: S
authors.lastname: Righi
authors.forename: Federica
authors.initials: F
authors.lastname: Sandri
authors.forename: Pier P
authors.initials: PP
authors.lastname: Piccaluga
authors.forename: Francesco
authors.initials: F
authors.lastname: Bacci
authors.forename: Elena
authors.initials: E
authors.lastname: Sabattini
authors.forename: Stefano A
authors.initials: SA
authors.lastname: Pileri
authors.forename: Teresa
authors.initials: T
authors.lastname: Marafioti
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism*; D045744:Cell Line, Tumor; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D060588:LIM Domain Proteins / Q000378:metabolism*; D007938:Leukemia / Q000378:metabolism* / Q000473:pathology; D008221:Lymphoid Tissue / Q000166:cytology / Q000378:metabolism*; D008223:Lymphoma / Q000378:metabolism* / Q000473:pathology; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D011817:Rabbits
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D060588:LIM Domain Proteins; C085117:LMO2 protein, human; D011518:Proto-Oncogene Proteins